AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2018
Jan 2, 2018
31523_dirs_2018-01-02_80461c9a-8ee7-40b2-af09-ee8a01f1fbc0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2017-12-28
Reporting Person: Crowley John F (Director, Chairman & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-12-28 | Common Stock | M | 13050 | $14.7507 | Acquired | 341051 | Direct |
| 2017-12-28 | Common Stock | S | 13050 | $14.7507 | Disposed | 328001 | Direct |
| 2017-12-29 | Common Stock | M | 5920 | $14.75 | Acquired | 333921 | Direct |
| 2017-12-29 | Common Stock | S | 5920 | $14.75 | Disposed | 328001 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-12-28 | Stock Options (right to buy) | $3.53 | M | 13050 | Disposed | 2023-01-28 | Common Stock (13050) | Direct |
| 2017-12-29 | Stock Options (right to buy) | $3.53 | M | 5920 | Disposed | 2023-01-28 | Common Stock (5920) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 64895 | Indirect |
Footnotes
F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.
F2: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.76. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F3: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.76. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: This price of $14.75 is the sole purchase price for the transactions reported on this line.
F5: This price of $14.75 is the sole sale price for the transactions reported on this line.